<bill session="115" type="s" number="1115" updated="2019-04-18T16:36:06Z">
  <state datetime="2017-05-11">REFERRED</state>
  <status>
    <introduced datetime="2017-05-11"/>
  </status>
  <introduced datetime="2017-05-11"/>
  <titles>
    <title type="official" as="introduced">A bill to improve access to prescription drugs.</title>
    <title type="short" as="introduced">Making Pharmaceutical Markets More Competitive Act</title>
    <title type="short" as="introduced">Making Pharmaceutical Markets More Competitive Act</title>
    <title type="display">Making Pharmaceutical Markets More Competitive Act</title>
  </titles>
  <sponsor bioguide_id="C001035"/>
  <cosponsors>
    <cosponsor bioguide_id="C001095" joined="2017-05-11"/>
    <cosponsor bioguide_id="F000457" joined="2017-05-11"/>
    <cosponsor bioguide_id="M001170" joined="2017-05-11"/>
  </cosponsors>
  <actions>
    <action datetime="2017-05-11">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2017-05-11" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="SSHR" name="Senate Health, Education, Labor, and Pensions" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill type="s" session="115" relation="unknown" number="934"/>
    <bill type="h" session="115" relation="identical" number="2562"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Administrative remedies"/>
    <term name="Congressional oversight"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Government information and archives"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2017-05-11T04:00:00Z" status="Introduced in Senate">Making Pharmaceutical Markets More Competitive Act

This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to&#160;prioritize the review of generic drug applications and supplements&#160;with respect to&#160;drugs that are in a shortage or for which there are not more than three approved drugs.

The holder of an approved drug application must notify the FDA within 180 days of withdrawing or transferring the application or withdrawing the drug from sale.

The FDA must maintain a list of generic drugs with three or fewer holders of approved applications.</summary>
  <committee-reports/>
</bill>
